These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 27134701)

  • 41. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis.
    Galvin Z; Rajakumar R; Chen E; Adeyi O; Selzner M; Grant D; Sapisochin G; Greig P; Cattral M; McGilvray I; Ghanekar A; Selzner N; Lilly L; Patel K; Bhat M
    Liver Transpl; 2019 Jan; 25(1):56-67. PubMed ID: 30609189
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation.
    Aguiar D; Martínez-Urbistondo D; D'Avola D; Iñarrairaegui M; Pardo F; Rotellar F; Sangro B; Quiroga J; Herrero JI
    Ann Transplant; 2017 Mar; 22():141-147. PubMed ID: 28302995
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Management of de novo malignancies after liver transplantation.
    Pillai AA
    Transplant Rev (Orlando); 2015 Jan; 29(1):38-41. PubMed ID: 25510578
    [TBL] [Abstract][Full Text] [Related]  

  • 44. De Novo Malignancies After Liver Transplantation With 14 Cases at a Single Center.
    Liu ZN; Wang WT; Yan LN;
    Transplant Proc; 2015 Oct; 47(8):2483-7. PubMed ID: 26518956
    [TBL] [Abstract][Full Text] [Related]  

  • 45. De Novo Malignancies After Liver Transplantation: A Single Institution Experience.
    Egeli T; Unek T; Ozbilgin M; Agalar C; Derici S; Akarsu M; Unek IT; Aysin M; Bacakoglu A; Astarcıoglu I
    Exp Clin Transplant; 2019 Feb; 17(1):74-78. PubMed ID: 29237362
    [TBL] [Abstract][Full Text] [Related]  

  • 46. De Novo Malignancies Screening After Liver Transplantation for Alcoholic Liver Disease: A Comparative Opportunistic Study.
    Renaud L; Hilleret MN; Thimonier E; Guillaud O; Arbib F; Ferretti G; Jankowski A; Chambon-Augoyard C; Erard-Poinsot D; Decaens T; Boillot O; Leroy V; Dumortier J
    Liver Transpl; 2018 Dec; 24(12):1690-1698. PubMed ID: 30207421
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Review of Standardized Incidence Ratios (SIR) of non-lymphoid de novo malignancies after liver transplantation: Structured analysis of global differences.
    Patel JA; Daoud D; Jain A
    Transplant Rev (Orlando); 2022 Jan; 36(1):100670. PubMed ID: 34688986
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk of virus and non-virus related malignancies following immunosuppression in a cohort of liver transplant recipients. Italy, 1985-2014.
    Taborelli M; Piselli P; Ettorre GM; Lauro A; Galatioto L; Baccarani U; Rendina M; Shalaby S; Petrara R; Nudo F; Toti L; Sforza D; Fantola G; Cimaglia C; Agresta A; Vennarecci G; Pinna AD; Gruttadauria S; Risaliti A; Di Leo A; Burra P; Rossi M; Tisone G; Zamboni F; Serraino D;
    Int J Cancer; 2018 Oct; 143(7):1588-1594. PubMed ID: 29693248
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The 28-year incidence of de novo malignancies after liver transplantation: A single-center analysis of risk factors and mortality in 1616 patients.
    Rademacher S; Seehofer D; Eurich D; Schoening W; Neuhaus R; Oellinger R; Denecke T; Pascher A; Schott E; Sinn M; Neuhaus P; Pratschke J
    Liver Transpl; 2017 Nov; 23(11):1404-1414. PubMed ID: 28590598
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.
    Kauffman HM; Cherikh WS; Cheng Y; Hanto DW; Kahan BD
    Transplantation; 2005 Oct; 80(7):883-9. PubMed ID: 16249734
    [TBL] [Abstract][Full Text] [Related]  

  • 51. De novo malignancies after organ transplantation: focus on viral infections.
    Piselli P; Busnach G; Fratino L; Citterio F; Ettorre GM; De Paoli P; Serraino D;
    Curr Mol Med; 2013 Aug; 13(7):1217-27. PubMed ID: 23278452
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decision tree analysis to stratify risk of de novo non-melanoma skin cancer following liver transplantation.
    Tanaka T; Voigt MD
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):607-615. PubMed ID: 29362916
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Skin cancer in immunosuppressed transplant patients: Vigilance matters.
    Unlu O; Roach EC; Okoh A; Olayan M; Yilmaz B; Uzunaslan D; Shatnawei A
    World J Hepatol; 2015 Apr; 7(4):717-20. PubMed ID: 25866609
    [TBL] [Abstract][Full Text] [Related]  

  • 54. De Novo Head and Neck Cancer After Liver Transplant With Antibody-Based Immunosuppression Induction.
    Graham RC; Mella JS; Mangus RS
    Transplant Proc; 2018 Dec; 50(10):3661-3666. PubMed ID: 30577252
    [TBL] [Abstract][Full Text] [Related]  

  • 55. De novo tumors are a major cause of late mortality after orthotopic liver transplantation.
    Baccarani U; Adani GL; Serraino D; Lorenzin D; Gambato M; Buda A; Zanus G; Vitale A; Piselli P; De Paoli A; Bresadola V; Risaliti A; Toniutto P; Cillo U; Bresadola F; Burra P
    Transplant Proc; 2009 May; 41(4):1303-5. PubMed ID: 19460546
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    Dobrindt EM; Biebl M; Rademacher S; Denecke C; Andreou A; Raakow J; Kröll D; Öllinger R; Pratschke J; Chopra SS
    Int J Organ Transplant Med; 2020; 11(2):71-80. PubMed ID: 32832042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Survival Benefit of Early Cancer Detection Through Regular Endoscopic Screening for De Novo Gastric and Colorectal Cancers in Korean Liver Transplant Recipients.
    Jung DH; Hwang S; Song GW; Ahn CS; Moon DB; Ha TY; Kim KH; Park GC; Kim BS; Park IJ; Lim SB; Kim JC; Yoo MW; Byeon JS; Jung HY; Lee GH; Myung SJ; Choe J; Choi JY; Park HW; Lee SG
    Transplant Proc; 2016; 48(1):145-51. PubMed ID: 26915860
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection.
    Moscicki AB; Flowers L; Huchko MJ; Long ME; MacLaughlin KL; Murphy J; Spiryda LB; Gold MA
    J Low Genit Tract Dis; 2019 Apr; 23(2):87-101. PubMed ID: 30907775
    [TBL] [Abstract][Full Text] [Related]  

  • 59. De novo malignancies after intestinal and multivisceral transplantation.
    Abu-Elmagd KM; Zak M; Stamos JM; Bond GJ; Jain A; Youk AO; Ezzelarab M; Costa G; Wu T; Nalesnik MA; Mazariegos GV; Sindhi RK; Marcos A; Demetris AJ; Fung JJ; Reyes JD
    Transplantation; 2004 Jun; 77(11):1719-25. PubMed ID: 15201672
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk factors associated with the development of skin cancer after liver transplantation.
    Mithoefer AB; Supran S; Freeman RB
    Liver Transpl; 2002 Oct; 8(10):939-44. PubMed ID: 12360438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.